Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)

Edmund InghamInvesting Group LeaderFollow5ShareSavePlay(18min)Comments(3)SummaryI must make the Novo Nordisk A/S Sell thesis due to mounting operational, competitive, and strategic setbacks, despite past GLP-1-driven outperformance.NVO's revenue and profit growth have sharply decelerated, with 2025 guidance repeatedly downgraded and 2026 outlook implying the prospect of a trough year.Intensifying competition from Eli Lilly, manufacturing disadvantages, price cuts, and patent expiries erode NVO's market share and long-term positioning.Large institutional holders may exit, and with no clear catalysts for recovery, NVO lacks near-term upside despite apparent valuation discounts.Haggerston BioHealth members get exclusive access to our real-world portfolio. See all our investments here » yuriz/iStock via Getty Images Investment Overview: Understanding Rationale For A Sell Call On Novo Stock Part 1 - Semaglutide's Meteoric Rise Was Unsustainable First, let me preface this analysis by stating that I hold some Novo Nordisk A/S (This article was written byEdmund Ingham14.8K FollowersFollowEdmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.